GB0601394D0 - Therapeutic delivery of carbon monoxide - Google Patents

Therapeutic delivery of carbon monoxide

Info

Publication number
GB0601394D0
GB0601394D0 GBGB0601394.0A GB0601394A GB0601394D0 GB 0601394 D0 GB0601394 D0 GB 0601394D0 GB 0601394 A GB0601394 A GB 0601394A GB 0601394 D0 GB0601394 D0 GB 0601394D0
Authority
GB
United Kingdom
Prior art keywords
carbon monoxide
therapeutic delivery
therapeutic
delivery
monoxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0601394.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sheffield
Hemocorm Ltd
Original Assignee
University of Sheffield
Hemocorm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sheffield, Hemocorm Ltd filed Critical University of Sheffield
Priority to GBGB0601394.0A priority Critical patent/GB0601394D0/en
Publication of GB0601394D0 publication Critical patent/GB0601394D0/en
Priority to EP07700404A priority patent/EP1978952A2/en
Priority to CNA2007800106818A priority patent/CN101466372A/zh
Priority to JP2008551859A priority patent/JP2009523841A/ja
Priority to US12/223,171 priority patent/US8389572B2/en
Priority to PCT/GB2007/000198 priority patent/WO2007085806A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0601394.0A 2006-01-24 2006-01-24 Therapeutic delivery of carbon monoxide Ceased GB0601394D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB0601394.0A GB0601394D0 (en) 2006-01-24 2006-01-24 Therapeutic delivery of carbon monoxide
EP07700404A EP1978952A2 (en) 2006-01-24 2007-01-23 Therapeutic delivery of carbon monoxide
CNA2007800106818A CN101466372A (zh) 2006-01-24 2007-01-23 一氧化碳的治疗性给予
JP2008551859A JP2009523841A (ja) 2006-01-24 2007-01-23 一酸化炭素の治療的供給
US12/223,171 US8389572B2 (en) 2006-01-24 2007-01-23 Therapeutic delivery of carbon monoxide
PCT/GB2007/000198 WO2007085806A2 (en) 2006-01-24 2007-01-23 Therapeutic delivery of carbon monoxide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0601394.0A GB0601394D0 (en) 2006-01-24 2006-01-24 Therapeutic delivery of carbon monoxide

Publications (1)

Publication Number Publication Date
GB0601394D0 true GB0601394D0 (en) 2006-03-01

Family

ID=36010856

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0601394.0A Ceased GB0601394D0 (en) 2006-01-24 2006-01-24 Therapeutic delivery of carbon monoxide

Country Status (6)

Country Link
US (1) US8389572B2 (enExample)
EP (1) EP1978952A2 (enExample)
JP (1) JP2009523841A (enExample)
CN (1) CN101466372A (enExample)
GB (1) GB0601394D0 (enExample)
WO (1) WO2007085806A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US7968605B2 (en) 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
EP2319518A1 (en) 2002-02-04 2011-05-11 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
GB2395432B (en) 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20070207217A1 (en) * 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
CA2534415A1 (en) * 2003-08-04 2005-02-17 Northwick Park Institute For Medical Research Therapeutic delivery of carbon monoxide
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
GB0613362D0 (en) * 2006-07-05 2006-08-16 Hemocorm Ltd Therapeutic delivery of carbon monoxide
WO2008130261A1 (en) * 2007-04-24 2008-10-30 Alfama - Investigaçao E Desenvolvimento De Produtos Farmaceuticos Lda. Treatment of infections by carbon monoxide
ATE555795T1 (de) * 2007-07-24 2012-05-15 Alfama Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Verhinderung von magengeschwüren mit kohlenmonoxid
US8697747B2 (en) 2009-03-05 2014-04-15 The Uab Research Foundation Enhancing coagulation or reducing fibrinolysis
JP2011152261A (ja) * 2010-01-27 2011-08-11 Nippon Koden Corp 携帯型生体信号測定・送信システム
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
PT2699242T (pt) 2011-04-19 2018-01-22 Alfama Inc Moléculas de libertação de monóxido de carbono e utilizações das mesmas
PL216649B1 (pl) * 2011-06-06 2014-04-30 Univ Warszawski Nowe kompleksy rutenu, sposób ich wytwarzania oraz zastosowanie w reakcji metatezy olefin
ES2628634T3 (es) 2011-07-21 2017-08-03 Alfama, Inc. Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
DE102012004132A1 (de) * 2012-02-29 2013-08-29 Friedrich-Schiller-Universität Jena Kohlenstoffmonoxid freisetzende Materialien und deren Verwendung
US20150173674A1 (en) * 2013-12-20 2015-06-25 Diabetes Sentry Products Inc. Detecting and communicating health conditions
DE102014008685A1 (de) 2014-06-13 2015-12-17 Lorenz Meinel Freisetzungssystem für therapeutisches Gas
US10881314B2 (en) * 2014-12-30 2021-01-05 General Electric Company Common display unit for a plurality of cableless medical sensors
EP3319613B1 (en) 2015-07-07 2023-02-22 The Research Foundation for The State University of New York Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
US10842812B2 (en) 2015-08-12 2020-11-24 The General Hospital Corporation Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
JP6796772B2 (ja) * 2016-08-23 2020-12-09 パナソニックＩｐマネジメント株式会社 運動テスト評価システム、運動テスト評価装置、運動テスト評価方法及びコンピュータプログラム
WO2020146758A1 (en) 2019-01-10 2020-07-16 The General Hospital Corporation Methods to treat mitochondrial-associated dysfunctions or diseases

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870180A (en) 1955-10-13 1959-01-20 Ethyl Corp Process for the preparation of hydrocarbon manganese carbonyl compounds
US3278570A (en) 1961-04-11 1966-10-11 Ethyl Corp Molybdenum pentacarbonyl compounds and process for preparing same
US3452079A (en) 1964-06-15 1969-06-24 Merck & Co Inc Acetic acid type compounds
GB1118728A (en) 1966-04-28 1968-07-03 James Kaye Improvements in or relating to the shaping of thermoplastic sheeting
CH536294A (de) 1968-09-13 1973-04-30 Schering Ag Verfahren zur Herstellung von racemischen und optisch aktiven 4,6-Dichlor-4,6-östradienen
US3829504A (en) 1970-06-04 1974-08-13 Int Flavors & Fragrances Inc Novel di-lower alkyl and lower alkylene acetals of 2-and 3-phenyl-pentenals
US3694232A (en) 1970-06-04 1972-09-26 Int Flavors & Fragrances Inc Flavoring methods and compositions containing 3-phenyl pentenals
US3980583A (en) 1974-02-19 1976-09-14 Mobil Oil Corporation Complexed metals bonded to inorganic oxides
NL7802482A (nl) 1977-03-17 1978-09-19 Klosa Josef Preparaat voor de profylaxis en therapie van acne vulgaris en werkwijze voor de profylaxis en therapie van acne vulgaris met behulp van pyridinaldehyden.
US4312989A (en) 1979-08-21 1982-01-26 The United States Of America As Represented By The Secretary Of The Army Pharmacologically active amine boranes
EP0034238B1 (en) 1979-12-21 1985-04-17 Duke University Pharmacologically active amine-carboxyboranes
US4322411A (en) 1980-04-25 1982-03-30 Burroughs Wellcome Co. Anti-inflammatory nucleosides
US4613621A (en) 1981-09-18 1986-09-23 Hoerrmann Wilhelm Fatty aldehydes and acids in the treatment of neurological and inflammatory diseases
DE3139358C2 (de) 1981-10-02 1984-06-07 Dragoco Gerberding & Co Gmbh, 3450 Holzminden Verwendung von 1,1-Di(C↓1↓-C↓6↓-alkyl)-2-phenyl-ethan-Derivaten als Riechstoffe
US4535167A (en) 1981-12-14 1985-08-13 Merck & Co. Inc. Chiral, N-protected, N-substituted α-amino acids
US4649151A (en) 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
GB8407557D0 (en) 1984-03-23 1984-05-02 Hayward J A Polymeric lipsomes
US4647555A (en) 1984-10-25 1987-03-03 The United States Of America As Represented By The Secretary Of The Army Esters of boron analogues of amino acids
US4657902A (en) 1985-03-25 1987-04-14 The Rockefeller University Therapeutic use of tin mesoporphyrin
US4709083A (en) 1986-05-19 1987-11-24 The United States Of America As Represented By The Secretary Of The Army Method of making boron analogues
US4699903A (en) 1986-06-20 1987-10-13 The Rockefeller University Therapeutic use of tin diiododeuteroporphyrin
US4668670A (en) 1986-06-20 1987-05-26 The Rockefeller University Tin diiododeuteroporphyrin and therapeutic use thereof
JPH0670025B2 (ja) 1987-08-07 1994-09-07 鐘紡株式会社 ベンゾチアゾ−ル誘導体および該化合物を有効成分とする抗リウマチ剤
US5350767A (en) 1987-11-19 1994-09-27 Aktiebolaget Draco Derivatives of cysteine
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5086060A (en) 1989-07-25 1992-02-04 Eastman Kodak Company Compound and method for treating skin for acne or psoriasis
US5010073A (en) 1989-10-05 1991-04-23 The Rockefeller University Use of liposomes as carriers for metalloporphyrins
US5362732A (en) 1989-12-20 1994-11-08 University Of North Carolina At Chapel Hill Boronated compounds
HU211084B (en) 1990-04-20 1995-10-30 Brezo Process for producing oral pharmaceutical composition of bone strengthening activity
DE4014762A1 (de) 1990-05-05 1991-11-07 Martin Prof Dr Wenzel Verbindungen zur strahlentherapie oder diagnostik durch absorption von moessbauer-strahlung
US5102670A (en) 1990-09-14 1992-04-07 Abraham Nader G Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels
US5254706A (en) 1991-05-10 1993-10-19 Boron Biologicals, Inc. Process of making phosphite-borane compounds
EP0746324A1 (en) 1991-09-13 1996-12-11 Boron Biologicals, Inc. Method of combatting osteoporosis and other disease states in mammalian subjects, utilizing organic boron compounds
GB2271351A (en) 1992-10-08 1994-04-13 Merck Patent Gmbh Carbocyclyl-phenyl-pyrazines and liquid crystalline media
GB9221327D0 (en) 1992-10-10 1992-11-25 Harden Richard C Letter receptacle
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
FR2707085B1 (fr) 1993-06-30 1995-08-18 Adir Nouveaux dérivés d'alpha amino acides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
GB9317686D0 (en) 1993-08-25 1993-10-13 Johnson Matthey Plc Pharmaceutical compositions
US6284752B1 (en) 1993-08-25 2001-09-04 Anormed Inc. Pharmaceutical compositions comprising metal complexes
US6417182B1 (en) 1993-08-25 2002-07-09 Anormed Inc. Pharmaceutical compositions comprising metal complexes
JP3775796B2 (ja) 1993-10-06 2006-05-17 ニコックス エス エイ 抗炎症活性及び／又は鎮痛活性を有する硝酸エステル類及びそれらの製造方法
US5631284A (en) 1993-10-06 1997-05-20 University Of British Columbia Compositions and methods for relaxing smooth muscles
US5811463A (en) 1993-10-06 1998-09-22 University Of British Columbia Compositions and method for relaxing smooth muscles
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5891689A (en) 1994-04-12 1999-04-06 Innovir Laboratories, Inc. Heme-bearing microparticles for targeted delivery of drugs
RU2145595C1 (ru) 1994-05-10 2000-02-20 Никокс С.А. Нитроксисоединения и фармацевтическая композиция на их основе, имеющие противовоспалительную, анальгетическую и антитромбоцитарную активности
DE4421433C1 (de) 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
PL318293A1 (en) 1994-07-25 1997-06-09 Alvin J Glasky Carbon monoxide dependent guanilyl cyclase modifiers
US6338963B1 (en) 1994-07-25 2002-01-15 Neotherapeutics, Inc. Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
US5801184A (en) 1994-07-25 1998-09-01 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5447939A (en) 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US6066333A (en) 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US5664563A (en) 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5670664A (en) 1995-09-08 1997-09-23 University Of Maryland Biotechnology Institute Photosensitive organic compounds that release carbon monoxide upon illumination
DE19540475A1 (de) 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
US5767157A (en) 1996-01-16 1998-06-16 Van Moerkerken; Arthur Arthritic pain prevention method and compositions
IT1276071B1 (it) 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria
US20020193363A1 (en) 1996-02-26 2002-12-19 Bridger Gary J. Use of nitric oxide scavengers to modulate inflammation and matrix metalloproteinase activity
ATE314060T1 (de) 1996-03-20 2006-01-15 Harvard College Triarylmethanverbindungen zur behandlung von krebs, aktinischer keratose und kaposisarkom
US5888982A (en) 1996-04-01 1999-03-30 President And Fellows Of Harvard College Regulation of vascular smooth muscle cell heme oxygenase-1
JP2000510448A (ja) 1996-04-05 2000-08-15 ザ ジェネラル ホスピタル コーポレーション 異常ヘモグロビン症の治療
US5756492A (en) 1996-09-09 1998-05-26 Sangstat Medical Corporation Graft survival prolongation with porphyrins
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
US6344178B1 (en) 1997-04-25 2002-02-05 Mallinckrodt Inc. Method for the preparation of facial metal tricarbonyl compounds and their use in the labelling of biologically active substrates
IT1292377B1 (it) 1997-06-19 1999-02-08 Nicox Sa Composizioni farmaceutiche a base di prostaglandine
IT1292426B1 (it) 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
US6203991B1 (en) 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
WO2000021965A1 (en) 1998-10-13 2000-04-20 Brown University Research Foundation Substituted perhalogenated phthalocyanines
AU1131400A (en) 1998-10-23 2000-05-15 Procter & Gamble Company, The Fragrance pro-accords and aldehyde and ketone fragrance libraries
JP2003500335A (ja) 1998-12-17 2003-01-07 サングスタット メディカル コーポレイション ヘムオキシゲナーゼ活性の調節による移植片の生存を強化する方法
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
CA2367282A1 (en) 1999-03-19 2000-09-28 Simon Fricker Pharmaceutical compositions comprising metal complexes
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
IL148971A0 (en) 1999-10-05 2002-11-10 Mallinckrodt Inc Carbon monoxide source for preparation of transition-metal-carbonyl-complexer
US6484747B2 (en) 2000-04-05 2002-11-26 Jerry S. Bridgers Medical gas utility stand
US6518269B1 (en) 2000-07-28 2003-02-11 University Of Arizona Foundation Cancer treatment
US6645938B2 (en) 2000-10-10 2003-11-11 Zymogenetics, Inc. Protection against ischemia and reperfusion injury
US20040122091A1 (en) 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
FR2816212A1 (fr) 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
CN1507348A (zh) 2001-03-30 2004-06-23 ɣ����ҽҩ��˾ 用于治疗血管性、炎性和免疫疾病的一氧化碳生成性组合物
WO2002080923A1 (de) * 2001-04-07 2002-10-17 Universitätsklinikum Charitè Substanzen zur therapie von erkrankungen, die durch hochproliferierende zellen verursacht werden
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US7238469B2 (en) 2001-06-21 2007-07-03 Beth Israel Deaconess Medical Center, Inc. Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
US8246969B2 (en) 2001-11-16 2012-08-21 Skinmedica, Inc. Compositions containing aromatic aldehydes and their use in treatments
US20030157154A1 (en) 2002-01-04 2003-08-21 Bryan Fuller Compositions containing hydroxy aromatic aldehydes and their use in treatments
US7968605B2 (en) 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
EP2319518A1 (en) * 2002-02-04 2011-05-11 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
US20080026984A1 (en) 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
KR20040096571A (ko) 2002-02-13 2004-11-16 베쓰 이스라엘 디코니스 메디칼 센터 인크 혈관 질환을 치료하는 방법
US20040143025A1 (en) 2002-04-01 2004-07-22 Roland Buelow Carbon monoxide generating compunds for treatment of vascular, inflammatory and immune disorders
ES2546280T3 (es) 2002-04-15 2015-09-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monóxido de carbono para su uso en un método para tratar íleo
ITMI20020960A1 (it) 2002-05-07 2003-11-07 Univ Degli Studi Milano Aldeidi lineari poliinsature e loro derivati ad attivita' antiradicalica e antitumorale
CA2485465A1 (en) 2002-05-17 2003-11-27 Yale University Methods of treating hepatitis
CA2487413A1 (en) 2002-06-05 2003-12-18 Yale University Methods of treating angiogenesis, tumor growth, and metastasis
JP4323271B2 (ja) 2002-09-27 2009-09-02 花王株式会社 バレロラクトン化合物及び香料組成物
AU2003283982A1 (en) 2002-11-07 2004-06-03 University Of Pittsburgh Of The Commonwealth System Of High Education Treatment for hemorrhagic shock
GB2395431A (en) 2002-11-20 2004-05-26 Northwick Park Inst For Medica Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide
GB2395432B (en) 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20070207217A1 (en) 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
US7670631B2 (en) 2003-03-12 2010-03-02 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists
US7709534B2 (en) 2003-04-28 2010-05-04 University Of The West Indies Method of treating strongyloides infections and medicaments therefor
CA2534415A1 (en) 2003-08-04 2005-02-17 Northwick Park Institute For Medical Research Therapeutic delivery of carbon monoxide
CA2560525A1 (en) 2004-03-18 2005-09-29 The University Court Of The University Of Glasgow Immunosuppressive cytokine
US20090238785A1 (en) 2004-06-24 2009-09-24 Flexitral, Inc. Novel Aldehydic Musks and Derivatives Thereof
US20070207993A1 (en) 2005-12-20 2007-09-06 Alfama - Investigacao E Desenvolvimetno De Productos Farmaceuticos Lda Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
GB0613362D0 (en) 2006-07-05 2006-08-16 Hemocorm Ltd Therapeutic delivery of carbon monoxide
WO2008069688A2 (en) 2006-12-06 2008-06-12 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
WO2008130261A1 (en) 2007-04-24 2008-10-30 Alfama - Investigaçao E Desenvolvimento De Produtos Farmaceuticos Lda. Treatment of infections by carbon monoxide
ATE555795T1 (de) 2007-07-24 2012-05-15 Alfama Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Verhinderung von magengeschwüren mit kohlenmonoxid

Also Published As

Publication number Publication date
WO2007085806A3 (en) 2007-12-27
US8389572B2 (en) 2013-03-05
US20110015263A1 (en) 2011-01-20
WO2007085806A2 (en) 2007-08-02
JP2009523841A (ja) 2009-06-25
EP1978952A2 (en) 2008-10-15
CN101466372A (zh) 2009-06-24

Similar Documents

Publication Publication Date Title
GB0613362D0 (en) Therapeutic delivery of carbon monoxide
EP2101855A4 (en) ADMINISTRATION OF ANTI-THERAPY
GB2455238B (en) Patient monitor
IL195052A0 (en) Patient customized therapeutic regimens
IL197316A0 (en) Buprenophine-wafer for drug substitution therapy
EP2046259A4 (en) PATIENTS LIEGE
GB0625659D0 (en) Therapeutic compounds and their use
GB0602178D0 (en) Therapeutic treatment
PT2954932T (pt) Utilização terapêutica de diaminofenotiazinas
IL195247A0 (en) Inhaler
HUE038232T2 (hu) Inhalátor
IL193747A0 (en) New therapeutic combinations for the treatment of depression
EP2035082A4 (en) OXYGEN THERAPY WITH ULTRASOUND
GB2434754B (en) Inhaler
GB0608655D0 (en) Therapeutic Treatment
IL197125A0 (en) Drug combinations for treating airway diseases
EP2123295A4 (en) THERAPEUTIC AGENT FOR INTERSTITIAL PNEUMONIA
GB0610909D0 (en) Therapeutic treatment
AP2006000208S (en) Inhaler
GB0609121D0 (en) Peptide Therapy
GB0706185D0 (en) Therapeutic delivery of carbon monoxide
AU311731S (en) Inhaler
GB0610376D0 (en) Therapeutic treatment
GB0614538D0 (en) Therapeutic Compounds And Their Use
GB2437806B (en) Novel therapeutic delivery system

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)